CN Patent

CN120265291A — 喹唑啉酮化合物的新用途和制剂

Assigned to F Hoffmann La Roche AG · Expires 2025-07-04 · 1y expired

What this patent protects

本发明涉及(3R)‑N‑[2‑氰基‑4‑氟‑3‑(3‑甲基‑4‑氧代‑喹唑啉‑6‑基)氧基‑苯基]‑3‑氟‑吡咯烷‑1‑磺酰胺或其药用盐，其用于局部晚期实体瘤、特别是有脑转移的黑色素瘤的治疗的新用途中。本发明还涉及包含(3R)‑N‑[2‑氰基‑4‑氟‑3‑(3‑甲基‑4‑氧代‑喹唑啉‑6‑基)氧基‑苯基]‑3‑氟‑吡咯烷‑1‑磺酰胺或其药用盐的药物组合物。

USPTO Abstract

本发明涉及(3R)‑N‑[2‑氰基‑4‑氟‑3‑(3‑甲基‑4‑氧代‑喹唑啉‑6‑基)氧基‑苯基]‑3‑氟‑吡咯烷‑1‑磺酰胺或其药用盐，其用于局部晚期实体瘤、特别是有脑转移的黑色素瘤的治疗的新用途中。本发明还涉及包含(3R)‑N‑[2‑氰基‑4‑氟‑3‑(3‑甲基‑4‑氧代‑喹唑啉‑6‑基)氧基‑苯基]‑3‑氟‑吡咯烷‑1‑磺酰胺或其药用盐的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN120265291A
Jurisdiction
CN
Classification
—
Expires
2025-07-04
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.